A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) (DUPLEX-AD)
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants With Moderate to Severe AD
Sponsor: Janssen Research & Development, LLC
A PHASE2 clinical study on Dermatitis, Atopic, this trial is ongoing. The trial is conducted by Janssen Research & Development, LLC and has accumulated 9 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Mar 2026 — Present [monthly]
Active Not Recruiting PHASE2
-
Feb 2026 — Mar 2026 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Nov 2025 — Feb 2026 [monthly]
Recruiting PHASE2
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE2
-
Jun 2025 — Aug 2025 [monthly]
Recruiting PHASE2
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE2
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE2
First recorded
Feb 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen Research & Development, LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alicante, Spain , Alpharetta, United States , Arlington, United States , Bad Bentheim, Germany , Barrie, Canada , Berlin, Germany , Boardman, United States , Bramsche, Germany , Buenos Aires, Argentina , Calgary, Canada and 49 more locations